Results 271 to 280 of about 20,388,994 (310)
Some of the next articles are maybe not open access.

Antifibrotics for Chronic Hepatitis C

Clinics in Liver Disease, 2009
Development and testing of antifibrotic agents for the treatment of chronic hepatitis C have generally been targeted toward hepatic stellate cells, transforming growth factor-beta, the inflammatory response, or extracellular matrix accumulation. Although several agents such as interferon-gamma, long-term pegylated interferon, and caspase inhibitors ...
openaire   +2 more sources

Nitazoxanide for chronic hepatitis C

Cochrane Database of Systematic Reviews, 2014
Hepatitis C infection is a disease of the liver caused by the hepatitis C virus. The estimated number of chronically infected people with hepatitis C virus worldwide is about 150 million people. Every year, another three to four million people acquire the infection. Chronic hepatitis C is a leading cause of liver-related mortality and morbidity.
Kristiana, Nikolova   +3 more
openaire   +2 more sources

Hepatitis C virus genotypes in chronic hepatitis C of children

Journal of Viral Hepatitis, 1996
SUMMARY.Several hepatitis C virus (HCV) genotypes have been recently identified and genotype 1b has been correlated with severe liver disease and a poor response to interferon therapy. HCV infection in children is an interesting model for evaluation of the relationship between HCV genotypes and liver disease, because of its relatively short duration ...
BORTOLOTTI, FLAVIA   +10 more
openaire   +5 more sources

Hepatic sarcoidosis associated with chronic hepatitis C

Journal of Gastroenterology, 2002
A 57-year-old woman with sarcoidosis was referred because of the appearance of multiple small low-attenuation areas in the liver on computed tomography (CT). A liver biopsy specimen showed chronic active hepatitis accompanied by sarcoid granulomas. The patient received prednisolone and, later, interferon-alpha.
Shinwa, Yamada   +5 more
openaire   +2 more sources

Economics of chronic hepatitis B and hepatitis C

Journal of Hepatology, 2007
Although not all patients develop progressive liver disease, chronic hepatitis B and chronic hepatitis C infections cause substantial morbidity and mortality worldwide. To address this need, many new antiviral treatments have become available over the past 10 years.
Arathi, Rajendra, John B, Wong
openaire   +2 more sources

Treatment for chronic hepatitis C

Current Gastroenterology Reports, 2003
Approximately four million Americans have been exposed to the hepatitis C virus (HCV) and are anti-HCV positive; almost three million are chronically infected and HCV RNA positive. Treatment for chronic hepatitis C has improved rapidly over the past 12 years from interferon monotherapy, with a sustained virologic response (SVR) rate of about 10% in the
openaire   +2 more sources

Treatment of chronic hepatitis C

Journal of Hepatology, 1991
alpha-Interferon given subcutaneously at doses between 1-3 million units leads to responses in about 50% of patients suffering from chronic hepatitis C. A 24-week treatment is frequently (approx. 50%) followed by relapses reducing the percentage of lasting responders to approx. 20%.
openaire   +2 more sources

Chronic Hepatitis C

2021
Chronic hepatitis C (C-HCV) is caused by an RNA virus, genotype 1a being the most common in the United States. The infection is transmitted by parenteral exposure to contaminated blood products, body fluids, and supplies used in procedures. It becomes chronic in 80% of the patients.
openaire   +1 more source

Chronic Hepatitis C

2016
Infection with hepatitis C virus (HCV) accounts for 40% of cases of chronic liver disease in the United States and is now the most common indication for liver transplantation. Estimates suggest that 4 million people (1.8%) of the American population are or have been infected with HCV.
Athwal, Varinder; id_orcid 0000-0002-1684-721X   +1 more
openaire   +2 more sources

Hepatitis C (chronic).

BMJ clinical evidence, 2018
About 60% to 85% of people infected with hepatitis C virus will go on to develop chronic hepatitis C, which is now believed to affect 3% of the world's population.We conducted a systematic overview and aimed to answer the following clinical questions: What are the effects of interferon-free treatments in treatment-naïve people with chronic hepatitis C ...
Alan Hoi Lun, Yau   +2 more
openaire   +1 more source

Home - About - Disclaimer - Privacy